Charles River Laboratories (CRL) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $345.37 +1.68%
EPS Growth %: +22.2%
Financial Fact:
Income from continuing operations, net of tax: 37.69M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: +22.2%
Financial Fact:
Income from continuing operations, net of tax: 37.69M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $2.75, $0.03 better than the analyst estimate of $2.72. Revenue for the quarter came in at $913.9 million versus the consensus estimate of $910.1 million.
GUIDANCE:
Charles River Laboratories sees FY2022 EPS of $11.50-$11.75, versus the consensus of $11.64.
- Revenue growth, reported 13.5% – 15.5%
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- BioNTech and Bristol Myers Squibb report Phase 2 data for pumitamig in NSCLC
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
